Association between sidedness and survival among chemotherapy refractory metastatic colorectal cancer patients treated with trifluridine/tipiracil or regorafenib
TAS-102 first provided a better survival benefit in chemotherapy refractory patients with mCRC across all sidedness. Further prospective studies are warranted to validate our conclusions.
Authors
- Ben‐Chang Shia (ORCID: https://orcid.org/0000-0003-2854-8361)
- Hsin‐Pao Chen
- Meng‐Che Hsieh (ORCID: https://orcid.org/0000-0002-1626-3396)
- Kai‐Yuan Hsiao (ORCID: https://orcid.org/0009-0002-3611-2007)
- Kuang-Wen Liu
- Wei-Shan Chang (ORCID: https://orcid.org/0009-0004-7196-9633)
- Hao-Yun Liang
- Kun-Ming Rau
Institutions
- Fu Jen Catholic University (TW)
- E-Da Hospital (TW)
- MTS Systems (United States) (US)
- I-Shou University (TW)
Publication Details
- Journal
- The Oncologist
- Published
- 2024-08-15
- DOI
- https://doi.org/10.1093/oncolo/oyae235
- Citations
- 2
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.57